Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278185 · ClinicalTrials.gov registry record · Phase 2
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
NCT02278185 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 19 participants.
The verdict
NCT02278185, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
Study Summary
This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulating sugar levels, and body weight. Previous studies have shown that patients with prostate cancer, who have been treated with standard medical therapy that lowers testosterone levels, have an increased risk of these changes. Hormone therapy using enzalutamide may fight prostate cancer by blocking the use of testosterone by the tumor cells instead of lowering testosterone levels. It is not yet known whether prostate cancer patients who receive enzalutamide will have reduced incidence of metabolic syndrome than patients who receive standard androgen deprivation therapy.
Interventions
- DRUG Enzalutamide
- DRUG leuprolide acetate
- DRUG goserelin acetate
- DRUG triptorelin
- DRUG histrelin acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-11-11 |
| Est. Completion | 2024-07-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02278185
The ClinicalTrials.gov registry entry for NCT02278185 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Enzalutamide is the first listed.
NCT02278185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02278185 about?
NCT02278185 is a clinical study titled "Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer". This randomized phase II trial compares enzalutamide with standard androgen deprivation therapy in reducing incidence of metabolic syndrome in patients with prostate cancer that has spread to other places in the body. Metabolic syndrome is defined as changes in cholesterol, blood pressure, circulati...
What is the current status of trial NCT02278185?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2015-11-11. Estimated completion is 2024-07-18.
What interventions are being tested in trial NCT02278185?
The interventions under investigation include: Enzalutamide (DRUG), leuprolide acetate (DRUG), goserelin acetate (DRUG), triptorelin (DRUG), histrelin acetate (DRUG).
Who is sponsoring clinical trial NCT02278185?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.